Interferon-Gamma Response Assays: ELISA vs ELISPOT

The IFNG Response test toward M. Tuberculosis is modeled in the LB domain, in the TB-TAUG as the following:

ELISA:

ELISPOT:

There are several issues with this modeling:

1. Where do you show that this challenge assay is done against TB antigens?
2. CP domain has developed a new standard variable called Test Condition Agent/CNDAGT, which is used to map stimulating agents, like the values in ASSYAG, so this CP new variable can be added to LB?
3. Lastly, this is a immunological test, should this be represented in LB?
   1. Use NHOID to show the name of the bug (in this case M. tuberculosis.) to which the INFg response is evoked? If we model this test in IS, what about IFNG test in lab. We need to draw the line where if we are running a routine lab test looking for IFNg level it goes to LB vs IFNg response test toward a specific, known bug then it goes to IS? If this test remains in LB, should NHOID be added to LB in order to show the name of the bug? I remember this being discussed by Jon/Bess when they worked on the TB TAUG.

If we were to model this in IS:

Similarly if we were to model Jozef's request for https://loinc.org/95971-8/ - SARS CoV-2 stimulated gamma interferon [Presence] in Blood